- Completed €1.5 billion sale of Feed Enzymes on June 2, 2025.
- €1 billion share buyback program started in April 2025, to finish by January 2026.
- Focus on innovation-led growth and strategic exits in 2025.
- €200 million from self-help programs supports €2.4 billion Adjusted EBITDA outlook.
Financial Performance
In the first half of 2025, the company reported strong organic sales and earnings growth. A significant milestone was the completion of the €1.5 billion sale of the Feed Enzymes business on June 2, 2025. Additionally, a €1 billion share buyback program was initiated in April 2025, with an accelerated completion target set for January 2026.
Strategic Focus
The company is concentrating on innovation-led growth and strategic portfolio adjustments. This includes exiting the Animal Nutrition & Health sector, as announced at the 2024 Capital Markets Day. The focus remains on leveraging synergies and optimizing the portfolio to align with key market trends in nutrition, health, and beauty.
Outlook
For the full year 2025, the company maintains an outlook of approximately €2.4 billion in Adjusted EBITDA. This projection is supported by a €200 million contribution from self-help programs, which are part of the broader strategy to enhance operational efficiency and drive growth.
